Bone loss accompanying medical therapies.
Dawson-Hughes
B
B
D000280:Administration, Inhalation; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects*; D001862:Bone Resorption / Q000517:prevention & control; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects*; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control*; D000077268:Pamidronate; D011471:Prostatic Neoplasms / Q000188:drug therapy; D014222:Triamcinolone Acetonide / Q000009:adverse effects*
D018931:Antineoplastic Agents, Hormonal; D004164:Diphosphonates; D005938:Glucocorticoids; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide; D014222:Triamcinolone Acetonide; D000077268:Pamidronate